title: Signaling through the lymphotoxin beta receptor induces the death of some adenocarcinoma tumor lines.
abstract: Surface lymphotoxin (LT) is a heteromeric complex of LT-alpha and LT-beta chains that binds to the LT-beta receptor (LT-beta-R), a member of the tumor necrosis factor (TNF) family of receptors. The biological function of this receptor-ligand system is poorly characterized. Since signaling through other members of this receptor family can induce cell death, e.g., the TNF and Fas receptors, it is important to determine if similar signaling events can be communicated via the LT-beta-R. A soluble form of the surface complex was produced by coexpression of LT-alpha and a converted form of LT-beta wherein the normally type II LT-beta membrane protein was changed to a type I secreted form. Recombinant LT-alpha 1/beta 2 was cytotoxic to the human adenocarcinoma cell lines HT-29, WiDr, MDA-MB-468, and HT-3 when added with the synergizing agent interferon (IFN) gamma. When immobilized on a plastic surface, anti-LT-beta-R monoclonal antibodies (mAbs) induced the death of these cells, demonstrating direct signaling via the LT-beta-R. Anti-LT-beta-R mAbs were also identified that inhibited ligand-induced cell death, whereas others were found to potentiate the activity of the ligand when added in solution. The human WiDr adenocarcinoma line forms solid tumors in immunocompromised mice, and treatment with an anti-LT-beta-R antibody combined with human IFN-gamma arrested tumor growth. The delineation of a biological signaling event mediated by the LT-beta-R opens a window for further studies on its immunological role, and furthermore, activation of the LT-beta-R may have an application in tumor therapy.
authors.affiliation: Department of Immunology and Inflammation, Biogen, Cambridge, Massachusetts 02142, USA.
authors.forename: J L
authors.initials: JL
authors.lastname: Browning
authors.forename: K
authors.initials: K
authors.lastname: Miatkowski
authors.forename: I
authors.initials: I
authors.lastname: Sizing
authors.forename: D
authors.initials: D
authors.lastname: Griffiths
authors.forename: M
authors.initials: M
authors.lastname: Zafari
authors.forename: C D
authors.initials: CD
authors.lastname: Benjamin
authors.forename: W
authors.initials: W
authors.lastname: Meier
authors.forename: F
authors.initials: F
authors.lastname: Mackay
mesh_terms: D000230:Adenocarcinoma / Q000473:pathology; D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology; D017209:Apoptosis / Q000187:drug effects; D016923:Cell Death / Q000187:drug effects; D002460:Cell Line; D004305:Dose-Response Relationship, Drug; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D007371:Interferon-gamma / Q000494:pharmacology*; D007700:Kinetics; D053259:Lymphotoxin beta Receptor; D008233:Lymphotoxin-alpha / Q000276:immunology / Q000502:physiology*; D051379:Mice / Q000276:immunology; D018124:Receptors, Tumor Necrosis Factor / Q000187:drug effects / Q000502:physiology*; D011994:Recombinant Proteins / Q000494:pharmacology; D015398:Signal Transduction; D014407:Tumor Cells, Cultured
chemical_list: D000911:Antibodies, Monoclonal; C505697:LTBR protein, human; C505699:Ltbr protein, mouse; D053259:Lymphotoxin beta Receptor; D008233:Lymphotoxin-alpha; D018124:Receptors, Tumor Necrosis Factor; D011994:Recombinant Proteins; D007371:Interferon-gamma